GSK-1904529A is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. In cellular and animal models of multiple myeloma and Ewing’s sarcoma, GSK-1904529A induces cell cycle arrest and inhibits cell proliferation and tumor growth.
| Cas No. | 1089283-49-7 |
|---|---|
| Purity | ≥98% |
| Formula | C44H47F2N9O5S |
| Formula Wt. | 851.96 |
| IUPAC Name | N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]-2-methoxybenzamide |
| Synonym | GSK1904529A |
| Solubility | DMSO |
| Appearance | Yellow to pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | G7541 MSDS PDF |
|---|---|
| Info Sheet | G7541 Info Sheet PDF |
Sabbatini P, Rowand JL, Groy A, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res. 2009 May 1;15(9):3058-67. PMID: 19383820.
